AARTIPHARM Stock Overview
Engages in the manufacture and sale of active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Aarti Pharmalabs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹688.55 |
| 52 Week High | ₹721.70 |
| 52 Week Low | ₹371.10 |
| Beta | 0 |
| 11 Month Change | 6.30% |
| 3 Month Change | 19.65% |
| 1 Year Change | 77.01% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 138.87% |
Recent News & Updates
Shareholder Returns
| AARTIPHARM | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 3.1% | 2.4% | 1.0% |
| 1Y | 77.0% | 60.9% | 44.7% |
Return vs Industry: AARTIPHARM exceeded the Indian Pharmaceuticals industry which returned 60.9% over the past year.
Return vs Market: AARTIPHARM exceeded the Indian Market which returned 44.7% over the past year.
Price Volatility
| AARTIPHARM volatility | |
|---|---|
| AARTIPHARM Average Weekly Movement | 6.2% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 9.8% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: AARTIPHARM has not had significant price volatility in the past 3 months.
Volatility Over Time: AARTIPHARM's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 2,095 | Hetal Gala | www.aartipharmalabs.com |
Aarti Pharmalabs Limited, together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system (CNS) agents, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects.
Aarti Pharmalabs Limited Fundamentals Summary
| AARTIPHARM fundamental statistics | |
|---|---|
| Market cap | ₹62.40b |
| Earnings (TTM) | ₹2.25b |
| Revenue (TTM) | ₹19.50b |
27.7x
P/E Ratio3.2x
P/S RatioIs AARTIPHARM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AARTIPHARM income statement (TTM) | |
|---|---|
| Revenue | ₹19.50b |
| Cost of Revenue | ₹11.28b |
| Gross Profit | ₹8.22b |
| Other Expenses | ₹5.96b |
| Earnings | ₹2.25b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 24.86 |
| Gross Margin | 42.14% |
| Net Profit Margin | 11.55% |
| Debt/Equity Ratio | 16.2% |
How did AARTIPHARM perform over the long term?
See historical performance and comparison